Retatrutide Genopharm 20 mg

Retatrutide is an investigational triple-agonist peptide that activates the GLP-1, GIP and glucagon receptors simultaneously, placing it in the same metabolic peptide category as GLP-1 and GIP-based compounds but with a broader mechanism. This Genopharm pack contains one vial holding 20 mg of Retatrutide as a dry powder, together with a 2 ml ampoule of Sodium Chloride injection U.S.P. (0.9 % w/v) for reconstitution.

By acting on all three receptors at once, Retatrutide reduces appetite, increases satiety, promotes fat breakdown and supports blood sugar control more comprehensively than single- or dual-receptor peptides. Clinical research has shown dose-dependent weight reduction, with higher doses associated with greater results. The 20 mg vial is a multi-dose container: it holds several weekly doses rather than a single administration.

Key Benefits

• Triple mechanism (GLP-1, GIP and glucagon receptors) for a broader metabolic effect than single-target peptides
• Reduces appetite and increases feelings of fullness
• Promotes breakdown of fat reserves
• Supports improved metabolic rate and blood sugar control
• Dose-dependent results demonstrated in clinical research
• Solvent ampoule included in the pack; produced under GMP (Good Manufacturing Practice)

Instructions

• Vial content: 20 mg total. This is a multi-dose vial covering several weekly doses – it is not a single dose
• Recommended dosage: individualized and titrated upward from a low starting dose under medical guidance; doses studied in clinical trials run up to roughly 12 mg per week
• Frequency: once per week
• Cycle length: ongoing weekly dosing under medical guidance; duration set individually based on goals
• Reconstitution: mix with the supplied 2 ml sodium chloride ampoule, swirl gently (do not shake)
• Administration: subcutaneous injection into the abdomen, thigh or upper arm

Side Effects & Warnings

• Retatrutide is an investigational compound and is not an approved medicine in the EU
• Gastrointestinal disturbances (nausea, diarrhea, constipation) are the most commonly reported effects, usually mild to moderate and resolving over time
• Should only be used following consultation with a qualified healthcare professional to confirm dosage and rule out contraindications
• Not recommended during pregnancy or breastfeeding
• Individual response varies – start low and adjust gradually

Storage

Store the unmixed vial refrigerated at 2-8 °C, and keep the reconstituted solution refrigerated as well, using it within the recommended timeframe after mixing. For subcutaneous use only.